Literature DB >> 27678491

Evaluating Recall and Recognition Memory Using the Montreal Cognitive Assessment: Applicability for Alzheimer's and Huntington's Diseases.

Charles Van Liew1,2, Maya S Santoro3, Jody Goldstein4, Shea Gluhm4, Paul E Gilbert3, Jody Corey-Bloom4.   

Abstract

We sought to investigate whether the Montreal Cognitive Assessment (MoCA) could provide a brief assessment of recall and recognition using Huntington disease (HD) and Alzheimer disease (AD) as disorders characterized by different memory deficits. This study included 80 participants with HD, 64 participants with AD, and 183 community-dwelling control participants. Random-effects hierarchical logistic regressions were performed to assess the relative performance of the normal control (NC), participants with HD, and participants with AD on verbal free recall, cued recall, and multiple-choice recognition on the MoCA. The NC participants performed significantly better than participants with AD at all the 3 levels of assessment. No difference existed between participants with HD and NC for cued recall, but NC participants performed significantly better than participants with HD on free recall and recognition. The participants with HD performed significantly better than participants with AD at all the 3 levels of assessment. The MoCA appears to be a valuable, brief cognitive assessment capable of identifying specific memory deficits consistent with known differences in memory profiles.
© The Author(s) 2016.

Entities:  

Keywords:  Alzheimer disease; Huntington disease; Montreal Cognitive Assessment (MoCA); recall; recognition

Mesh:

Year:  2016        PMID: 27678491     DOI: 10.1177/1533317516668573

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  1 in total

1.  The Association between Montreal Cognitive Assessment Memory Scores and Hippocampal Volume in a Neurodegenerative Disease Sample.

Authors:  Aaron Ritter; Nanako Hawley; Sarah J Banks; Justin B Miller
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.